

Cushing Syndrome - Pipeline Insight, 2021

<https://marketpublishers.com/r/CC1A9BAB4F71EN.html>

Date: July 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: CC1A9BAB4F71EN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Cushing Syndrome - Pipeline Insight, 2021," report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Cushing Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Cushing Syndrome Understanding

Cushing Syndrome: Overview

Cushing syndrome is a constellation of clinical abnormalities caused by chronic high blood levels of cortisol or related corticosteroids. Cushing disease is Cushing syndrome that results from excess pituitary production of adrenocorticotrophic hormone (ACTH), generally secondary to a pituitary adenoma. Typical symptoms and signs include moon face and truncal obesity, easy bruising, and thin arms and legs. Diagnosis is by history of receiving corticosteroids or by finding elevated and/or relatively autonomous serum cortisol. Treatment depends on the cause.

'Cushing Syndrome - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication.

A detailed picture of the Cushing Syndrome pipeline landscape is provided which includes the disease overview and Cushing Syndrome treatment guidelines. The assessment part of the report embraces, in depth Cushing Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cushing Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Cushing Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Cushing Syndrome.

Cushing Syndrome Emerging Drugs Chapters

This segment of the Cushing Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cushing Syndrome Emerging Drugs

RECORLEV (levoketoconazole): Strongbridge Biopharma

RECORLEV (levoketoconazole), or COR-003, is an investigational cortisol synthesis inhibitor. It has received orphan drug designation from the FDA and the European Medicines Agency for the treatment of endogenous Cushing's syndrome. Ketoconazole is recommended for use in treating Cushing's syndrome,¹ but is not approved for that use in the US.

Relacorilant: Corcept Therapeutics

Relacorilant is a non-steroidal, selective modulator of the glucocorticoid receptor, the

receptor for cortisol which is activated when cortisol levels are high. Relacorilant does not bind to the body's other hormone receptors. Corcept is studying relacorilant as a potential treatment for a variety of serious disorders, including Cushing's syndrome and advanced adrenal, ovarian and pancreatic cancer. Relacorilant is proprietary to Corcept and is protected by composition of matter and method of use patents. Relacorilant has received orphan drug designation in the United States for the treatment of Cushing's syndrome and pancreatic cancer.

Further product details are provided in the report.....

Cushing Syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Cushing Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Cushing Syndrome

There are approx. 8+ key companies which are developing the therapies for Cushing Syndrome. The companies which have their Cushing Syndrome drug candidates in the most advanced stage, i.e. preregistration include, Strongbridge Biopharma.

Phases

DelveInsight's report covers around 8+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Cushing Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cushing Syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cushing Syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cushing Syndrome drugs.

Cushing Syndrome Report Insights

- Cushing Syndrome Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Cushing Syndrome Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Cushing Syndrome drugs?

How many Cushing Syndrome drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cushing Syndrome?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cushing Syndrome therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Cushing Syndrome and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Strongbridge Biopharma

Corcept Therapeutics

Crinetics Pharmaceuticals

Cyclacel Pharmaceuticals

Sparrow Pharmaceuticals

AstraZeneca

Key Products

RECORLEV (levoketoconazole)

Relacorilant

CRN 04894

Seliciclib

SPI-62

AZD 4017

Contents

Introduction

Executive Summary

Cushing Syndrome: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Late Stage Products (Preregistration)

Comparative Analysis

RECORLEV (levoketoconazole): Strongbridge Biopharma

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Seliciclib: Cyclacel Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

CRN-04894: Crinetics Pharmaceuticals

Product Description

Research and Development

Product Development Activities
Drug profiles in the detailed report.....
Preclinical and Discovery Stage Products
 Comparative Analysis
Drug name: Company name
 Product Description
 Research and Development
 Product Development Activities
Drug profiles in the detailed report.....

Inactive Products
 Comparative Analysis
Cushing Syndrome Key Companies
Cushing Syndrome Key Products
Cushing Syndrome- Unmet Needs
Cushing Syndrome- Market Drivers and Barriers
Cushing Syndrome- Future Perspectives and Conclusion
Cushing Syndrome Analyst Views
Cushing Syndrome Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Cushing Syndrome

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Cushing Syndrome
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Cushing Syndrome - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/CC1A9BAB4F71EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CC1A9BAB4F71EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970